HIF1A and neoplasm: In these studies, the researchers found that maximal HIF-1α inhibition and enhanced anti-tumor efficacy is best achieved with Topo 1 inhibitors possessing extended pharmacokinetics, or with a daily low-dose dosing regimen to achieve a higher overall drug level over a longer period of time [18].